According to recent multiple studies (Table 2), SGLT-2 inhibitors can lower the risk of HF hospitalization, and they have been recognized to exert multidimensional effects since approval of their usage in the United States [114,124]. This evidence concerns the gene SLC5A2 and hydrops fetalis.